NextCure lands Fast Track for ovarian ADC

NextCure said on April 7 that the FDA granted Fast Track designation to SIM0505 for women with platinum-resistant ovarian cancer, a hard corner of oncology where tumors have already learned how to live through the drugs that usually work first (markets.businessinsider.com). Fast Track does not mean approval. It means the agency sees a serious disease and an unmet need, and is willing to talk with the company more often as the program moves forward (fda.gov). That matters because SIM0505 is still early. The drug is in a first-in-human Phase 1 study, registered as NCT06792552, which began in February 2025 and is mainly designed to answer the basic questions every new cancer drug must face first: how safe it is, what dose patients can tolerate, how it moves through the body, and whether there are any early hints that it can shrink tumors (clinicaltrials.gov). NextCure has said it expects to begin dose optimization in ovarian cancer in the second quarter of 2026, which tells you where the program really is. It is not near the finish line. It is still trying to find the right lane (stocktitan.net). The reason the story is interesting anyway is the target. SIM0505 goes after cadherin-6, or CDH6, a cell-surface protein that shows up in ovarian cancer often enough to keep drawing drug developers back to it (sciencedirect.com). The drug is an antibody-drug conjugate, or ADC. That means one part is an antibody meant to find CDH6 on tumor cells, and the other part is a toxic payload meant to kill those cells after the antibody gets there. In SIM0505’s case, that payload is a proprietary topoisomerase 1 inhibitor, the same broad class of cell-killing chemistry that has powered several of the most important ADCs in cancer over the past few years (biospace.com). That promise comes with a catch. Topoisomerase-1 ADCs can work, but they are not gentle medicines, and the whole game is whether the targeting is good enough to widen the therapeutic window rather than just move toxicity around the body. NextCure and its partner Simcere say SIM0505 was designed for fast systemic clearance and a better therapeutic window, which is exactly the sort of claim that sounds good in a press release and still has to survive real patients in real clinics (biospace.com). Fast Track can speed meetings and paperwork. It cannot rescue a drug from safety problems. The disease setting explains why the FDA was willing to lean in. Platinum-resistant ovarian cancer is one of the clearest examples of unmet need in solid tumors. Most patients with epithelial ovarian cancer eventually relapse after platinum chemotherapy, and once the disease becomes platinum-resistant, treatment options narrow and outcomes worsen (ascopubs.org; jamanetwork.com). That is also why companies keep building new ADCs for this space. The biology is messy, the patients are heavily pretreated, and even modest activity can look meaningful if it lasts. SIM0505 is not alone in chasing CDH6. Other developers are already in the clinic with the same target, including raludotatug deruxtecan and CUSP06, both of which also use topoisomerase-1 payloads and are being tested in ovarian cancer (annalsofoncology.org; ascopubs.org). So the real significance of this designation is not that NextCure has found a secret door. It is that the company now has a faster route to show whether SIM0505 deserves to stay in a very crowded race, with Phase 1 data slated for presentation at ASCO in Chicago from May 29 to June 2, 2026 (biospace.com).